



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)
(AIM: HCM)**

Holding in Company

London, Monday, 31 March 2008: Chi-Med today announces that it received notification on 28 March 2008 that as at 27 March 2008, Lansdowne Partners Limited Partnership controlled 3,440,000 shares in Chi-Med, representing approximately 6.7% of the total issued shares of Chi-Med. These shares were registered under Morstan Nominees Limited, of which 3,284,492 shares were held on behalf of Lansdowne UK Equity Fund Limited and 155,508 shares were held on behalf of Lansdowne UK Equity Fund L.P. respectively.

Ends

Enquiries

Chi-Med
Christian Hogg, CEO

Telephone: +852 2121 8200

Citigate Dewe Rogerson
Anthony Carlisle
David Dible

Telephone: +44 (0) 20 7638 9571
+44 (0) 7973 611 888
+44 (0) 7967 566 919

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group focused on traditional Chinese medicine (“TCM”) based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med operates three core business segments: 1) China healthcare – the manufacture, distribution and marketing of pharmaceuticals and health supplements in China; 2) Drug R&D – the discovery and global development of novel drug in the oncology and auto-immune therapeutic areas; and 3) Consumer products – global retailing and distribution consumer health and personal care products derived from TCM and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.